ERBB2 and breast carcinoma: Considering these unique mechanisms, we hypothesized that heregulin could alter the efficacy of HER2‐ or HER3‐targeting drugs, and that the combined use of pertuzumab and patritumab could suppress cancer cell proliferation, better than each antibody alone, in heregulin‐expressing breast cancer.